Oradoxel (oral docetaxel/encequidar) / Athenex, Hanmi, PharmaEssentia - LARVOL DELTA

The Case for Chemotherapy Plus Immunotherapy for Patients With Low or Negative PD-L1 (HMP Global) - "At the Great Debates & Updates in Lung Cancer meeting in New York...Karen Reckamp, MD... debated in favor of using chemotherapy plus immunotherapy for patients with non-small cell lung cancer and PD-L1 expressions of <1% and 1% to 49%."

Video

Precision Medicine and Immunotherapy in mNSCLC: Bridging Gaps for Patients Without Driver Mutations : Episode 7 (AJMC) - "Specialists evaluate their clinical strategies for managing second-line driver-negative and initial PD-L1 negative patients."

Media quote

EGFR Exon 20 Insertion as a Therapeutic Target in Non-small Cell Lung Cancer - Episode 4: Current Treatments for EGFR Exon 20 Insertion+ NSCLC (Targeted Oncology) - "Joel Neal, MD, PhD: Let's go into treatment approaches. We covered a bit about how the patients have been treated historically, but I think it's worth going into our treatment approach in the first-line setting....Alexander I. Spira, MD, PhD, FACP: I'm a carboplatin-pemetrexed person. I'm sure most of us are. I usually shy away from the I/O [immuno-oncology] agents."

Video

[VIRTUAL] An open-label, pharmacokinetic study to determine the bioavailability, safety and tolerability of single dose oral docetaxel in metastatic prostate cancer (mPC) patients treated with IV docetaxel. (ASCO 2021) - "Oradoxel was well tolerated . Based on the results of this and related studies, Oradoxel 300mg/m2 in divided doses is being further evaluated in phase 2 studies."

Clinical • PK/PD data • Genito-urinary Cancer • Immunology • Oncology • Prostate Cancer • Solid Tumor

Athenex Presents Data on Oral Docetaxel and Oral Paclitaxel at ASCO2021 Virtual Scientific Program (GlobeNewswire) - P1, N=24; NCT02963168; Sponsor: Athenex, Inc; "Data were presented from the open-label, two-way crossover phase I pharmacokinetic study of oral docetaxel vs IV docetaxel, which demonstrated the drug was well tolerated with no dose limiting toxicities, or drug-related serious adverse events. The mean absolute bioavailability was 15.9% (range 8% to 25%) with PK exposure becoming non-linear at 300 mg/m2."

P1 data • Genito-urinary Cancer • Oncology • Prostate Cancer

A DRF Study to Evaluate Safety, Tolerability, PK, and Activity of Oradoxel Monotherapy in Subjects w Adv. Malignancies (clinicaltrials.gov) - P1; N=24; Recruiting; Sponsor: Athenex, Inc.; Trial completion date: Dec 2019 ➔ Apr 2020; Trial primary completion date: Apr 2019 ➔ Mar 2020

Clinical • Monotherapy • Trial completion date • Trial primary completion date